In an emerging trend, a recent survey conducted by Accolade, a healthcare program provider for employers, in collaboration with research firm Savanta, indicates a potential significant increase in the number of US employers offering coverage for obesity medications in 2024. Among these medications is Wegovy, produced by Novo Nordisk, a member of the GLP-1 drug class, which is currently generating substantial interest in the market.
The survey, which polled 502 employers, highlights that 43 percent of respondents are considering the inclusion of GLP-1 drugs in their healthcare coverage plans for 2024, compared to the current 25 percent who provide such coverage.
GLP-1s, scientifically referred to as glucagon-like peptide 1 agonists, are primarily utilized for the treatment of type 2 diabetes and weight management.
Accolade’s Associate Chief Medical Officer, James Wantuck, offers guidance to the 43 percent of employers planning to offer GLP-1 drug coverage next year. He recommends a physician-led approach that would determine appropriate candidates for GLP-1 medications and integrate them into a comprehensive health management plan.
The survey also reveals that nearly all employers currently covering GLP-1 drugs intend to continue offering this coverage in the upcoming year.
Employers opting to cover weight-loss drugs are bracing for an increase in their healthcare expenses due to the growing popularity of Wegovy.
Sales of Novo Nordisk’s Wegovy, as well as its diabetes medication Ozempic, both containing the active ingredient semaglutide, have experienced substantial growth over the past year. Ozempic is also being used “off label” for weight loss purposes.
Additionally, prescriptions for Eli Lilly’s Mounjaro, another GLP-1 diabetes drug expected to gain approval for weight loss in the United States later this year, have witnessed a significant surge.
Leading benefits consultant Aon forecasts that a one percentage point increase out of the predicted 8.5 percent rise in employer healthcare costs for the next year will be attributed to the greater utilization of weight-loss drugs by employees.
